Are the Calderbank Offers effective?
28 The relevant principles are not in dispute. VMS said that it largely agreed with the principles set out in SARB's written submissions on costs at paras 2 to 8. For present purposes, paragraphs 7 and 8 can be excluded because they address the principles relevant to whether the power under s 43 of the Federal Court of Australia Act 1976 (Cth) (FCA Act) extends to making costs orders against non-parties. VMS said that it also largely agreed with CoM's statement of the relevant principles in paras 2 to 5 of its written submissions as to costs. VMS also relies on the decision in Les Laboratoires Servier v Apotex Pty Ltd [2016] FCAFC 27; (2016) 247 FCR 61 (Servier v Apotex) at [297]-[306] and [329]-[331]; and Idenix Pharmaceuticals LLC v Gilead Sciences Pty Ltd (No 2) [2018] FCAFC 7. I refer to the written submissions referred to in this paragraph.
29 A brief summary of the key principles is as follows.
30 The wide discretion in awarding costs that is given to the Court by s 43 of the FCA Act is well established. However, that does not mean that there are no principles or practices to be applied in exercising that discretion (Servier v Apotex at [296] per Bennett, Besanko and Beach JJ). In Servier v Apotex, the Full Court said the following (at [297]-[298]):
There are two general approaches to the award of costs that have general application and have been the subject of numerous decisions:
(1) The successful party is generally entitled to its costs. That is, costs usually follow the event.
(4) It is also the case that a successful party may be awarded less than its costs, or there may be an order apportioning costs, on the basis of success on the issues.
This has been recently reiterated by the High Court (per French CJ, Kiefel, Nettle and Gordon JJ) in Firebird Global Master Fund II Ltd v Republic of Nauru (No 2) (2015) 90 ALJR 270 at [6], where their Honours observed that if the event of success cannot be seen as contestable, having regard to how separate issues have been determined, then:
There are no special circumstances to warrant a departure from the general rule, and good reasons not to encourage applications regarding costs on an issue-by-issue basis, involving apportionments based on degrees of difficulty of issues, time taken to argue them and the like.
(see also Idenix Pharmaceuticals LLC v Gilead Sciences Pty Ltd (No 2) [2018] FCAFC 7 at [3]).
31 There are many cases dealing with the circumstances in which this Court may exercise the power in s 43 of the FCA Act to award costs on an indemnity basis. With respect, in Anchorage Capital Partners Pty Limited v ACPA Pty Ltd (No2) [2018] FCAFC 112 the Full Court provided a helpful summary of relevant principles. The Full Court said (at [5]-[8]):
5 Section 43 of the Federal Court of Australia Act 1976 (Cth) confers a broad discretion on the Court to award costs in proceedings. In Re Wilcox; Ex parte Venture Industries Pty Ltd (No 2) (1996) 72 FCR 151, Black CJ at 152 stated the principles applicable to a claim for indemnity costs:
…it is well established that the starting point for any consideration of an application for indemnity costs is that in the ordinary case costs will follow the event and the Court will order the unsuccessful party to pay the costs of the successful party, on a party and party basis, a basis which will fall short of complete indemnity. Nevertheless, the Court has an absolute and unfettered jurisdiction in awarding costs, although the discretion must be exercised judicially. So indemnity costs may properly be awarded where there is some special or unusual feature in the case justifying the Court in exercising the discretion in that way.
6 A well-established circumstance justifying an award of indemnity costs is an imprudent refusal of an offer to compromise (Colgate-Palmolive Company v Cussons Pty Ltd (1993) 46 FCR 225 at 233 per Sheppard J). In such cases, a key question is whether the offeree's refusal of the offer was "unreasonable" when viewed in light of the circumstances existing at the time the offer was rejected (Black v Lipovac & Ors (1998) 217 ALR 386 at 432 per Miles, Heerey and Madgwick JJ; CGU Insurance Ltd v Corrections Corporation of Australia Staff Superannuation Ltd [2008] FCAFC 173 at [75] per Moore, Finn and Jessup JJ).
7 The circumstances to be taken into account in determining whether rejection of an offer was "unreasonable" cannot be stated exhaustively but may include, for example:
(f) the stage of the proceeding at which the offer was received;
(g) the time allowed to the offeree to consider the offer;
(h) the extent of the compromise offered;
(i) the offeree's prospects of success, assessed as at the date of the offer;
(j) the clarity with which the terms of the offer were expressed; and
(k) whether the offer foreshadowed an application for an indemnity costs in the event of the offeree rejecting it.
(Hazeldene's Chicken Farm Pty Ltd v Victorian WorkCover Authority (No 2) (2005) 13 VR 435 at [25] per Warren CJ, Maxwell P and Harper AJA; Beling v Sixty International S.A. (No 2) [2015] FCA 355 at [25] per Mortimer J).
8 An unsuccessful party is not liable to pay indemnity costs merely because it received an offer to settle on terms more favourable than it achieved at trial and rejected that offer (CGU Insurance at [75]; Black at [217]-[218]). As we observed in the Appeal Reasons, albeit in the context of r 25.14(2) of the FCRs, assessment of the "unreasonableness" of an offeree's refusal of a settlement offer is a broad-ranging inquiry that is not restricted to consideration of the extent or quantum of the compromise offered.
32 SARB's principal submission in relation to the Calderbank offer made on 15 March 2021 is that the first, second and fourth elements of the offer reflect the final outcome of the proceedings and that had VMS accepted SARB's offer in March 2021, it would have avoided the lengthy trial, subsequent appeal and all the costs and any costs orders associated therewith. In addition, SARB offered to pay VMS's costs of the proceedings up to the date of the offer on a party/party basis and to include in that VMS's costs in relation to PV3 and to pay VMS's costs of the hearing on quantum on a party/party basis. SARB submits that its liability for additional damages in relation to PV1 and PV2 is unlikely to be greater than the costs of the infringement action in relation to PV3 and that accepting SARB's offer would have put VMS in a more favourable position overall.
33 CoM submitted that the extent of the compromise contained in its Calderbank offer was significant. It offered to consent to declarations of infringement by PV1 and PV2, the grant of injunctive relief in respect of those versions and orders for any inquiry as to damages or an account of profits. The offer was also made on the basis that VMS discontinue its claim for additional damages against CoM and in fact such an order was made by the trial judge and there was no appeal to the Full Court from that finding. The offer contained a term that VMS's claims in relation to PV3 would be dismissed. CoM submitted that ultimately, the Full Court held that PV3 did not infringe the patents and that the risk that that would be the result was clearly pointed out to VMS in SARB's Calderbank offer of 15 March 2021. CoM further submitted that it is not necessary for it to establish that VMS's construction of claim 21 and related claims was hopeless or untenable. They contend that at the time of the offer, VMS was in a position to make an assessment of the prospects of successfully upholding its case of infringement by PV3 "about which there was no substantive factual dispute". In the circumstances, VMS's rejection of the compromise in the Calderbank offer was unreasonable.
34 VMS made the following submissions. First, it contends that it had achieved a better result than the offers in the Calderbank letters. As far as SARB is concerned, VMS succeeded in its claim for additional damages against SARB for infringement of both patents by PV1 and PV2, whereas SARB's offer had included a term that VMS discontinue this claim. There is no evidence to support SARB's assertion that its liability for additional damages is unlikely to be greater than the costs of the infringement action in relation to PV3. The Court cannot form a view as to the quantum of additional damages that may be payable by SARB and ought to assume that it may be substantial. VMS made a claim through its solicitors on 21 March 2021 that its losses in respect of PV1 and PV2 may well extend to all or part of PV3 as the fruits of PV1 and PV2.
35 Secondly, VMS contends that SARB's offer as to the payment of costs in the Calderbank offer does not assist its argument because SARB will achieve a similar result if its submissions as to costs are accepted (that is, 90% of the costs of the Application and the costs of the Cross-claim) and it is not possible at this stage to assess whether VMS will achieve a better or worse outcome.
36 Thirdly, VMS contends that CoM's Calderbank offer was not capable of being accepted if SARB's Calderbank offer was rejected. In those circumstances, the two offers must be considered together and VMS achieved a better result when that is done because SARB's offer required VMS to abandon the claim for additional damages against it.
37 Fourth, VMS contends that it was not unreasonable for it to reject the Calderbank offers in circumstances in which VMS was required to give up its claim for additional damages and the offers did not resolve the dispute and they left key matters open for determination in the future. For example, SARB's offer involved the parties agreeing to the form of orders reflecting the settlement should the offer be accepted. In addition, the Calderbank offers did not formulate the costs payable to VMS under the terms of the offers and the quantum payable by SARB and CoM for infringement of the first patent and the second patent by PV1 in the case of SARB and CoM, and PV2 in the case of SARB.
38 Fifth, VMS claims it was not in a position to commercially assess the significance of abandoning it claims in relation to PV3. It had been unable to obtain access to an unredacted form of Annexure A to the Verified Product Method Description which set out the volumes and dates of supply of PV1, PV2 and PV3. In addition, the first opportunity VMS had to test SARB's assertion that PV1, PV2 and PV3 did not infringe the patents was when SARB served an unverified Product Method Description on 4 March 2020.
39 Sixth, VMS contends that the offers did not represent a significant compromise because at the time of the offers, SARB had admitted that PV1 and PV2 infringed both patents and VMS had conceded that PV3 did not infringe the second patent. Furthermore, SARB had abandoned various grounds of invalidity and ultimately, SARB and CoM lost on defences that they had offered to abandon, for example, the authorisation defence.
40 Seventh, VMS contends that at the time of the offers, the scope of SARB's Cross-claim was unclear and still evolving.
41 Finally, VMS submitted that there was support for the construction of claims 21, 30, 31, and 32 for which it contended and the fact was that there were good prospects of success. They referred to the decision of the trial judge and also submitted that such contention was consistent with the decision in Vehicle Monitoring Systems Pty Ltd v SARB Management Group Pty Ltd [2020] FCA 408; (2020) 150 IPR 216 (at [198]).
42 SARB's response to a number of these submissions was as follows. With respect to the fourth matter, SARB submits that acceptance of the offer would have finally resolved the dispute as to liability and that was the issue at that time. With respect to the fifth matter, SARB submits that VMS did not need Mr Saxon Hill to be granted access to the confidential material to assess the significance of abandoning its claim in relation to PV3. With respect to the final matter, SARB submits that VMS was represented by experienced solicitors and counsel to whom it would have been apparent that the decision in Vehicle Monitoring Systems Pty Ltd v SARB Management Group Pty Ltd [2020] FCA 408; (2020) 150 IPR 216 (at [198]) was irrelevant because it related to "what was described in the specification, not claim scope".
43 CoM advanced the following submissions. With respect to the first matter, CoM points to the fact that VMS failed in its application for additional damages as against it.
44 With respect to the third matter, CoM submits that the offer was directed to resolving the trial as to liability in circumstances where that was taking place before the trial as to quantum. The amount of costs and the precise form of the injunctions did not affect the effectiveness of the offer.
45 With respect to the fifth matter, CoM submits that VMS accepts that it was in a position to test whether PV3 infringed the patents from at least a year before the offer was made and the relevant question was not one of commercially assessing the significance. That is irrelevant if the claims concerning PV3 properly construed meant that PV3 did not infringe the patents.
46 With respect to the sixth matter, CoM submits that its Calderbank offer did contain a significant compromise in that it conceded the validity of the patents, liability as to PV1 and PV2 and abandoned costs in relation to additional damages.
47 With respect to the seventh matter, CoM submits that the uncertainty of SARB's invalidity claim was irrelevant because the issue was one of construction and para (a) of its Calderbank offer involved an admission as to the validity of the two patents.
48 With respect to the final matter, CoM submits that the relevant question is not the prospects or otherwise of VMS succeeding on its claim with respect to PV3, but whether, in all the circumstances, including the terms of the offer, it was unreasonable for VMS to reject the offer.
49 In my opinion, the Calderbank offers are effective.
50 SARB's Calderbank offer was sent on 15 March 2021. That was seven days before the trial commenced. SARB restated its offer on 19 March 2021 after VMS had rejected SARB's Calderbank offer of 15 March 2021. VMS suggested that the correct date for SARB's Calderbank offer is 19 March 2021. I do not agree. There is no material difference between the offers.
51 In SARB's offer of 15 March 2021, the offer provides that it is open for acceptance until 10 am on 18 March 2021. That is a reasonable period for the offer to remain open having regard to the fact that the offer was made only seven days before the start of the trial. I did not understand VMS to suggest otherwise. By the offer, VMS is given notice that if it does not accept the offer and does not achieve a better result at the trial, then SARB will produce the letter to the Court on the question of costs and seek an order that VMS pay SARB's costs of the proceeding from the date of the letter on an indemnity basis. The Calderbank offer is expressed to be made without prejudice save as to costs and reference is made to the principles in Calderbank v Calderbank. I am satisfied that the offeree was given proper and adequate notice that the Calderbank offer may be relied upon to seek an order for costs on an indemnity basis. SARB's Calderbank letter makes it clear that it has admitted that should the claims of the patents in suit survive SARB's invalidity attack, PV1 and PV2 infringe various claims of VMS's patents. The letter states that the only live issues in dispute "in this regard" are SARB's defences relating to the deed of settlement dated 18 June 2014, being its "double recovery" defence and "authorisation" defence. SARB's Calderbank letter then focuses on whether PV3 infringes claims in the patents. It records that in SARB's mediation position paper it appears that VMS accepts that PV3 operates in the manner contended for by SARB, that is, vehicle overstay is identified by the handheld unit (i.e, the DCA), not the IGU (in-ground unit) (i.e, the DA). The offer goes on to say the following:
2.6 For the reasons articulated in our client's mediation position paper and supported by the evidence of our client's expert witness, Mr Jefferson Harcourt, your client's construction of claim 21 (and, by extension, claims 22 and 23) is wholly untenable. This strained reconstruction of the plain wording of the claim appears to have been devised only after our client provided detailed information about the workings of the Third Version, and does not withstand scrutiny. We are confident that the Court will construe claims 21 to 23 in accordance with the construction proffered by our client, such that the Third Version does not infringe these claims.
52 I am satisfied that SARB's Calderbank offer adequately explained SARB's position and the basis upon which it made the offer.
53 The same may be said of CoM's Calderbank offer. In the case of this Calderbank offer, it was stated that the offer was open for acceptance until 12 noon on Sunday, 21 March 2021. In view of the fact that the trial was due to commence on 22 March 2021, this was adequate time for VMS to consider the offer. I am satisfied that the offer gave sufficient notice to VMS that if CoM obtained a judgment as favourable or better than the offer, then it would rely on the offer on the question of costs, "including on an indemnity basis".
54 I am satisfied that both Calderbank offers are expressed in sufficiently clear terms. I reject VMS's submission that the requirement in SARB's Calderbank offer that the parties agree a form of orders reflecting the settlement makes the offer uncertain. Equally, I reject VMS's submission that the failure to quantify the quantum for the infringement of PV1 and PV2 makes the Calderbank offer uncertain. The fact of the matter is that there had been an order separating liability and quantum. The effect of VMS's submission overlooks that fact. Equally, I reject the argument that the failure to quantify costs renders the offer uncertain. An offer to pay an amount or to take some form of action plus costs to be agreed or taxed in the absence of agreement is sufficiently certain and is, in fact, often the type of offer which is made. I do not know whether it is suggested that CoM's Calderbank offer was uncertain. If it is, I reject the submission. VMS put a different point in relation to CoM's Calderbank offer and that was that in terms it could be accepted only if VMS accepted SARB's Calderbank offer.
55 A passage in the Calderbank offer and after CoM had referred to SARB's Calderbank offer of 15 March 2021, the following appears:
As is clear from our client's defence, our client's position with respect to non-infringement and validity is the same as SARB's. For the avoidance of doubt, if your client accepted SARB's offer:
(a) on the basis of SARB's admissions about SARB's products, our client would consent to appropriate orders that reflect that position (including any consequential procedural orders);
(b) our client would not independently seek to advance arguments based on SARB's cross-claim; and
(c) consistently with SARB's offer, our client would not press its authorisation and double recovery defences.
Later, in the Calderbank offer, and immediately prior to setting out the five elements of the offer, CoM states that its offer is intended to be read together with SARB's offer of 15 March 2021.
56 As I understand VMS's argument, it is that CoM's offer was conditional on VMS accepting SARB's offer and, in those circumstances, if SARB's case relying on its Calderbank offer fails, then CoM's case relying on its Calderbank offer also fails. In response, CoM submits that VMS relies on two matters in support of its argument and its response to those matters is that the first element involves open admissions to which VMS itself refers in its submissions when it says that the offers did not represent a significant compromise and gave as one example the fact that at the time of the offers, SARB had admitted that PV1 and PV2 infringed both patents. Furthermore, the reference to CoM's Calderbank offer being read together with SARB's Calderbank offer does not make the former conditional upon the acceptance of the latter. CoM's submission is that nowhere in the Calderbank offer is it stated that it may only be accepted if SARB's offer is accepted.
57 It seems to me that the difficulty for CoM is that para (a) of the offer states that it will consent to appropriate orders that reflect the position of SARB's admissions with respect to the validity of the two patents in suit and SARB's admissions of liability for infringement with respect to all uses of PV1 and PV2. That suggests to me that SARB's admissions as to validity and liability for infringement are an element of CoM's Calderbank offer. In other words, if VMS does not accept SARB's Calderbank offer, then SARB does not accept the validity of the two patents in suit or admit liability for infringement with respect to all uses of PV1 and PV2. Even if it is right to say that SARB had openly admitted liability for infringement with respect to all uses of PV1 and PV2, there was no open admission from SARB accepting the validity of the two patents in suit. I consider that CoM's Calderbank offer was contingent on SARB's offer being accepted.
58 I consider that both offers involved a genuine element of compromise. SARB offered to admit the validity of the two patents in suit and to pay various costs incurred by VMS. CoM offered to concede the validity of the patents and liability for infringement with respect to all uses of PV1 and PV2 and not to seek costs in relation to VMS's claim for additional damages against CoM, an issue upon which CoM was ultimately successful.
59 I turn now to consider whether the result in the trial was equal to or better than the offer. This is the first question but it has been convenient to deal with VMS's particular arguments first.
60 The principal matter that VMS put in this respect is that it had achieved a better result in the trial because it has a right to additional damages against SARB with respect to PV1 and PV2, whereas the offer required VMS to discontinue its claim for additional damages against SARB. CoM is not in the same position, although as I have stated, its offer is contingent upon VMS's acceptance of SARB's offer. SARB's response to this submission is that its liability for additional damages in relation to PV1 and PV2 is unlikely to be greater than the costs of the infringement action in relation to PV3 and that, in those circumstances, SARB's Calderbank offer would have put VMS in a more favourable position overall. In response, VMS submits that there is no evidence to support this assertion and the Court cannot form a view as to the quantum of additional damages that may be payable by SARB and ought to assume it may be substantial. In my opinion, VMS's assertion that its losses in respect of PV1 and PV2 may well extend to all or part of PV3 as the fruits of PV1 and PV2 is speculative and is not made any stronger by the fact that it was referred to in a letter from VMS's solicitors to SARB and CoM's respective solicitors on 21 March 2021. VMS further submits that SARB cannot rely on its offer to pay costs in the Calderbank letter for the reasons indicated previously (at [35]). In my opinion, SARB is correct that VMS's claim for additional damages is unlikely to exceed SARB's offer as to costs.
61 It seems to me that the contention that it is not possible to assess whether VMS will achieve a better or worse outcome, particularly in circumstances where there is a claim for additional damages and where, depending on the ultimate resolution of the quantum hearing, VMS itself might apply for a special costs order in relation to the totality of the proceedings, having regard to the lump sum offers it made in 2021, which were rejected, is no more than assertion and had VMS wished to advance this point, it should have articulated it and produced such evidence as it might have had available. For example, there was no development of the submission that VMS might apply for a special costs order or reference in detail to the lump sum offers referred to in the submission. I consider that SARB's offer (and therefore that of CoM) was equal to or better than the result VMS achieved at trial.
62 I also consider that VMS's rejection of the offer was unreasonable. In addition to the matters to which I have referred, there are the following considerations: (1) the Calderbank offers were made very close to trial and I cannot accept that VMS would not have had sufficient information to make an informed assessment as to whether PV3 infringed the Patent; (2) that issue was a concise one; and (3) the parties were facing a substantial and costly trial. In conclusion, I consider that the Calderbank letters are effective
63 That conclusion means that the first respondent should have its costs of the Application and Cross-claim on an indemnity basis from 15 March 2021 and the second respondent should have its costs on the Application and Cross-claim on an indemnity basis from 19 March 2021.
64 I recognise that there were issues in the Application upon which the applicant succeeded, but I do not consider that to be of any moment, because had the Calderbank offers been accepted, that would have brought the proceeding to an end as far as liability is concerned. As I have said, I consider that the allegation that PV3 infringed one or both of the Patents was the dominant feature of the Application. These features also apply in the case of the CoM and the same observations apply. I do not think that there is anything in my costs judgment which is inconsistent with this approach (VMS (No 9)). In my view, the whole context has changed as a result of the Full Court's decision that PV3 does not infringe either patent. Furthermore, I consider that CoM should have such costs as it has incurred on an indemnity basis in relation to the Cross-claim, even though it was not a cross-claimant in the Notice of cross-claim. The fact is that had the Calderbank offers been accepted, the proceeding would have been brought to an end as to liability at the time of or shortly after the Calderbank offers were made.